Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ.

Literature DB >> 23641041

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ.

Shivani Duggal, Thomas B Julian.

Abstract

Entities: Disease

Mesh：

Year: 2013 PMID： 23641041 PMCID： PMC3653826 DOI： 10.1093/jnci/djt098

Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506

× No keyword cloud information.

21 in total

1. Detection of ductal carcinoma in situ in women undergoing screening mammography.

Authors: Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller
Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506

2. Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast.

Authors: Grace L Smith; Benjamin D Smith; Bruce G Haffty
Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038

3. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors: B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544

4. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors: Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers
Journal: J Clin Oncol Date: 2006-06-26 Impact factor: 44.544

5. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.

Authors: J Boyages; G Delaney; R Taylor
Journal: Cancer Date: 1999-02-01 Impact factor: 6.860

6. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Authors: E R Fisher; J Dignam; E Tan-Chiu; J Costantino; B Fisher; S Paik; N Wolmark
Journal: Cancer Date: 1999-08-01 Impact factor: 6.860

7. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors: B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal: Lancet Date: 1999-06-12 Impact factor: 79.321

8. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Authors: D C Allred; G M Clark; A K Tandon; R Molina; D C Tormey; C K Osborne; K W Gilchrist; E G Mansour; M Abeloff; L Eudey
Journal: J Clin Oncol Date: 1992-04 Impact factor: 44.544

9. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Authors: Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle
Journal: Lancet Date: 2003-07-12 Impact factor: 79.321

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ.

1. Detection of ductal carcinoma in situ in women undergoing screening mammography.

2. Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast.

3. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

4. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

5. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.

6. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

7. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

8. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

9. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

10. Prospective study of wide excision alone for ductal carcinoma in situ of the breast.

1. DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

2. Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.

Review 3. Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures.

4. Identifying association model for single-nucleotide polymorphisms of ORAI1 gene for breast cancer.

5. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.